News >

Sznol Reflects on Immunotherapy Advances in mRCC

Angelica Welch
Published: Wednesday, Aug 08, 2018

Dr. Mario Sznol

Mario Sznol, MD
Immunotherapy is poised to become the standard of care for patients with metastatic renal cell carcinoma (mRCC), according to Mario Sznol, MD.

In addition to dual immunotherapy combinations, Sznol said that VEGF inhibitors are another potential pair for checkpoint inhibitors. PD-1/PD-L1 inhibitors can be combined with other receptor inhibitors, including bevacizumab (Avastin), sunitinib, cabozantinib (Cabometyx), and lenvatinib (Lenvima), Sznol explained. Cytokines, NKTR-214, IDO inhibitors, and interleukin 15 (IL-15), are also under consideration for combination strategies with PD-1/PD-L1 inhibitors.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication